According to the second trial decision of Dukarb on the 16th of this month, it is decided whether to release the core capacity at the same time.

With Boryung Kanarb's generic set to be released next month, attention is focused on the second trial of the patent dispute, which is three days away. This is because the decision of the patent court determines whether to release the Dukarb generic core capacity at the same time.

◆Dukarb's generic will be released sequentially after registering next month's benefit

According to the pharmaceutical industry on the 13th, the material patent of Boryung Kanarb expired as of the 1st of this month. In principle, a generic for Kana